tweenvest

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (SEHK: 3378)

Health Care · Biotechnology · CN

HK$24.88

-0.08% today · +44.7% 1Y

Public summary
A free snapshot of Hanx Biopharmaceuticals (Wuhan) Co., Ltd., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (SEHK: 3378) operates in the Biotechnology industry within the Health Care sector. The company is valued at $431.98M and employs 60 people.

Over the last twelve months the share price has gained 44.7%, trading between 13.48 and 33.80.

Tweenvest scores Hanx Biopharmaceuticals (Wuhan) Co., Ltd. across four factors: quality 53/100, value 100/100. Its strongest factor is value.

3378 price history

Dec 24, 2025 · 17.39Weekly closes 16.10 – 32.20Nov 13, 2026 · 24.88

Key figures

Market cap
$431.98M
Revenue (TTM)
$10.75K
P/E
-23.70
EPS
-1.23
Dividend yield
—
Beta (5Y)
—
52-week high
HK$33.80
52-week low
HK$13.48
Avg volume (3M)
—
Shares outstanding
136.22M
Employees
60
Next earnings
—

About Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.

ISIN
CNE100007C34
Founded
2014
Listed since
Dec 23, 2025
Exchange
The Stock Exchange of Hong Kong Ltd.
Currency
HKD
CompanyMarket capPriceDay
Ever Supreme Bio Technology Co., LtdTPEX: 6712$452.94MNT$148.00+1.72%
Qurient Co., Ltd.KOSDAQ: A115180$441.89M₩14,510.00-11.74%
Qingdao Vland Biotech INC.SHSE: 603739$440.25MCN¥11.60+0.87%
Jiangsu Sihuan Bioengineering Co., LtdSZSE: 000518$435.38MCN¥2.82+0.71%
Kexing Biopharm Co., Ltd.SHSE: 688136$430.33MCN¥14.45-1.43%
Shanghai Bao Pharmaceuticals Co., Ltd.SEHK: 2659$430.25MHK$10.44-8.42%
Prothena Corporation plcNasdaqGS: PRTA$428.77M$8.35+1.09%
Gongwin Biopharm Holdings Co., Ltd.TPEX: 6617$428.25MNT$116.50-6.80%

Browse every Biotechnology company →